Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline characteristics for patients (men aged ≥ 50 years) with T2D hospitalized (n = 460) in the SUA groups were summarized in Table 1.Patient characteristics based on SUA groupsCharacteristicsTotalMean ± SDPG1(< 240 μmol/L)G2(240-299 μmol/L)G3(300-359 μmol/L)G4(360-419 μmol/L)G5(420-479 μmol/L)G6(≥ 480 μmol/L)N460417397957678Age, years61.283 ± 7.77761.268 ± 7.30160.247 ± 7.2761.474 ± 7.17862.253 ± 8.71360.013 ± 7.26762.077 ± 8.4020.34TLBMD, T-value−1.08 ± 1.19−1.402 ± 0.871−1.414 ± 1.135−0.997 ± 1.255−0.971 ± 1.214−0.822 ± 1.231−1.087 ± 1.1670.013FNBMD, T-value m−1.2−1.3−1.4−1.1−1.1−1.1−1.30.249THBMD, T-value m−0.8−1−1.1−0.8−0.7−0.8−0.80.354TBMD, g/cm21.11 ± 0.0961.094 ± 0.081.098 ± 0.0921.106 ± 0.0911.131 ± 0.1111.124 ± 0.0961.098 ± 0.0890.074TLM, g42,625.991 ± 6050.02139,982.054 ± 7549.0942,099.574 ± 6312.6942,190.333 ± 5105.72342,726.101 ± 5241.95343,765.838 ± 5942.99243,817.657 ± 6627.1410.011TFM, g20,588.745 ± 6064.28818,201.078 ± 5207.56719,335.558 ± 6267.69619,692.629 ± 5415.42820,218.264 ± 5825.22822,440.075 ± 6093.18522,778.422 ± 6348.52 < 0.001TFr, %30.905 ± 4.99829.04 ± 5.36929.803 ± 5.09930.286 ± 4.82330.572 ± 4.97132.374 ± 4.88632.662 ± 4.278 < 0.001Trunk/LegsFr, %1.194 ± 0.1361.14 ± 0.1171.163 ± 0.1351.205 ± 0.1291.202 ± 0.1191.197 ± 0.1391.227 ± 0.160.007Trunk/LimbFr, %1.445 ± 0.2161.387 ± 0.2061.391 ± 0.2351.456 ± 0.2041.427 ± 0.1791.471 ± 0.2271.509 ± 0.230.006A/G, %1.225 ± 0.1771.18 ± 0.1291.192 ± 0.1771.217 ± 0.1881.242 ± 0.1761.245 ± 0.2111.252 ± 0.1420.115H(cm)165.336 ± 5.568164.439 ± 5.32165.973 ± 5.538165.119 ± 5.494165.211 ± 5.023165.382 ± 5.697165.59 ± 6.3580.796Wt(kg)67.572 ± 11.50663.373 ± 9.67965.918 ± 12.54266.247 ± 10.63967.303 ± 10.34670.48 ± 11.42270.468 ± 12.7830.003BMI, kg/m224.685 ± 3.8223.456 ± 3.62523.812 ± 3.55224.252 ± 3.39224.689 ± 3.93825.775 ± 4.04325.618 ± 3.9180.001Waistline, cm90.128 ± 10.41487.037 ± 9.24488.897 ± 12.83589.216 ± 9.59890.153 ± 9.85891.842 ± 10.0492.341 ± 10.0450.051Hipline, cm95.067 ± 7.80693.744 ± 6.86295.151 ± 10.35593.753 ± 6.68694.755 ± 7.03896.289 ± 8.0296.505 ± 7.2710.125SUA, μmol/L378.389 ± 115.659192.512 ± 40.237270.452 ± 16.276329.371 ± 19.585388.126 ± 17.417448.487 ± 17.904557.91 ± 86.077 < 0.001TC, mmol/L5.055 ± 1.3554.853 ± 1.1485.028 ± 1.4424.936 ± 1.3865.208 ± 1.4084.959 ± 1.2425.236 ± 1.3720.462TG, mmol/L m1.661.221.351.531.7151.9752.3 < 0.001LDLc, mmol/L2.708 ± 0.962.649 ± 0.9132.755 ± 1.092.571 ± 0.9482.818 ± 0.9282.664 ± 0.8462.774 ± 1.0110.543ALP, U/L84.223 ± 36.71782.415 ± 28.21588.863 ± 45.29788.34 ± 43.73481.745 ± 34.03178.392 ± 27.56884.231 ± 32.620.445SCr, μmol/L m81716874829497.5 < 0.001FBG, mmol/L m8.599.339.569.388.0157.8657.635 < 0.0012hPG, mmol/L17.592 ± 5.59419.183 ± 5.67719.327 ± 5.62818.001 ± 5.26417.046 ± 5.58216.322 ± 5.13116.486 ± 5.8750.002HbA1c, % m9.510.2511.110.78.958.58.4 < 0.001FINS, umol/l m8.0810.5457.776.857.5459.488.9150.1792hINS, umol/l m24.35520.88514.6319.5825.3831.7729.43 < 0.001FC-peptide, nmol/L m1.9651.471.351.592.082.052.645 < 0.0012hC-peptide, nmol/L m4.63.7353.613.724.955.7855.91 < 0.001Calcium levels, mmol/L2.262 ± 0.1542.229 ± 0.1512.244 ± 0.1812.252 ± 0.1212.288 ± 0.1562.27 ± 0.1642.268 ± 0.1510.27425(OH)D levels, ng/mL30.118 ± 11.19631.241 ± 10.58431.346 ± 11.17929.63 ± 11.0129.49 ± 11.95531.096 ± 11.17828.84 ± 10.9270.651Duration of T2D, months m603636487236840.079Abbreviations: SUA serum uric acid, SD standard deviation, G group N number, TLBMD total lumbar bone mineral density, FNBMD femoral neck bone mineral density, THBMD total hip bone mineral density, TBMD whole body bone mineral density, TLM total lean mass, TFM total fat mass, TFr total fat ratio, Fr fat ratio, A/G android/gynoid ratio, H height, Wt weight, BMI body mass index, TC total cholesterol, TG triglyceride, LDL-c low-density lipoprotein cholesterol, ALP alkaline phosphatase, SCr serum creatinine, FBG fasting blood glucose, HbA1c glycosylated hemoglobin type A1C, FINS fasting serum insulin, 25(OH)D 25-hydroxy vitamin D, T2D type 2 diabetesm median, P-value < 0.05 was considered statistically significant

Source: Patients’ characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Influence of serum uric acid on bone mineral density across body mass index categories in men with type 2 diabetes: a cross-sectional study

Source: Article title.

The participants were divided into six groups according to SUA levels.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Influence of serum uric acid on bone mineral density across body mass index categories in men with type 2 diabetes: a cross-sectional study

Cross-sectional study · BMC Musculoskeletal Disorders · 2025

Original publication title

Influence of serum uric acid on bone mineral density across body mass index categories in men with type 2 diabetes: a cross-sectional study

Yujun Qin; Chunmiao Huang; Wenhe Wei; Yi Zhang

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

SUA was correlated with TLBMD in T2D men aged ≥ 50 years. Among patients with BMI 24 to 27.999 kg/m2, the SUA concentrations between 360 to 419 μmol/L might have a protective effect on TLBMD.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To explore whether SUA was associated BMD across BMI categories in men aged ≥ 50 years with type 2 diabetes (T2D).

Source: Purpose

Abstract: What methods does the paper describe?

The participants were divided into six groups according to SUA levels. Analyses were adjusted for the covariates including weight(Wt), total lean mass(TLM), total fat mass(TFM), total fat ratio(TFr), A/G and a range of other baseline laboratory findings.

Source: Methods

Abstract: Results

SUA was associated with total lumbar BMD(TLBMD) (p = 0.013). In the BMI(24 to 27.999 kg/m2) group, SUA was significantly associated with TLBMD (p = 0.02). There was no correlation between SUA and whole-body BMD, as well as femoral neck BMD and total hip BMD. In the BMI < 24 kg/m2 group, the highest TLBMD value was observed when SUA levels ranged from 420 µmol/L to 479 µmol/L. While BMI:24 to 27.999 kg/m2, the highest TLBMD value was showed in the SUA(360-419 μmol/L) group based on adjusted models.

The SUA(300-360 μmol/L) group exhibited the highest TLBMD value among the patients with BMI ≥ 28 kg/m2.

Source: Results

Abstract: Conclusion

SUA was correlated with TLBMD in T2D men aged ≥ 50 years. Among patients with BMI 24 to 27.999 kg/m2, the SUA concentrations between 360 to 419 μmol/L might have a protective effect on TLBMD.

Source: Conclusion
Authors’ abstract

Background

The impact of different serum uric acid(SUA) concentrations on bone mineral density(BMD) varied across different BMI categories, which might provide useful insights for clinical uric acid-lowering treatments.

Purpose

To explore whether SUA was associated BMD across BMI categories in men aged ≥ 50 years with type 2 diabetes (T2D).

Methods

The participants were divided into six groups according to SUA levels. Analyses were adjusted for the covariates including weight(Wt), total lean mass(TLM), total fat mass(TFM), total fat ratio(TFr), A/G and a range of other baseline laboratory findings.

Results

SUA was associated with total lumbar BMD(TLBMD) (p = 0.013). In the BMI(24 to 27.999 kg/m2) group, SUA was significantly associated with TLBMD (p = 0.02). There was no correlation between SUA and whole-body BMD, as well as femoral neck BMD and total hip BMD. In the BMI < 24 kg/m2 group, the highest TLBMD value was observed when SUA levels ranged from 420 µmol/L to 479 µmol/L. While BMI:24 to 27.999 kg/m2, the highest TLBMD value was showed in the SUA(360-419 μmol/L) group based on adjusted models.

The SUA(300-360 μmol/L) group exhibited the highest TLBMD value among the patients with BMI ≥ 28 kg/m2.

Conclusion

SUA was correlated with TLBMD in T2D men aged ≥ 50 years. Among patients with BMI 24 to 27.999 kg/m2, the SUA concentrations between 360 to 419 μmol/L might have a protective effect on TLBMD.

Publication and source details

Original title: Influence of serum uric acid on bone mineral density across body mass index categories in men with type 2 diabetes: a cross-sectional study

Yujun Qin; Chunmiao Huang; Wenhe Wei; Yi Zhang

BMC Musculoskeletal Disorders · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Scientific Research Cultivation Project of Guangxi Health CommissionZ-M20221849

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:40:58.941128+00:00

DOI: 10.1186/s12891-025-09169-8 · PMC12616981